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Alzheimer’s disease (AD) is the leading cause of dementia among the elderly population; however,knowledge about genetic risk
factorsinvolvedindiseaseprogressionislimited.Weconductedagenome-wideassociationstudy(GWAS)usingclinicaldecline
as measured by changes in the Clinical Dementia Rating-sum of boxes as a quantitative trait to test for single-nucleotide
polymorphisms (SNPs) that were associated with the rate of progression in 822 Caucasian subjects of amnestic mild cognitive
impairment (MCI). There was no signiﬁcant association with disease progress for any of the recently identiﬁed disease
susceptibility variants in CLU, CR1, PICALM, BIN1, EPHA1, MS4A6A, MS4A4E or CD33 following multiple testing correction. We
did, however, identify multiple novel loci that reached genome-wide signiﬁcance at the 0.01 level. These top variants (rs7840202
at chr8 in UBR5: P¼4.27 10
 14; rs11637611 with a cluster of SNPs at chr15q23 close to the Tay–Sachs disease locus:
P¼1.07 10
 15; and rs12752888 at chr1: P¼3.08 10
 11) were also associated with a signiﬁcant decline in cognition as well
as the conversion of subjects with MCI to a diagnosis of AD. Taken together, these variants deﬁne approximately 16.6% of the
MCIsub-population withafasterrateofdeclineindependentoftheotherknowndiseaseriskfactors.Inadditiontoprovidingnew
insights into protein pathways that may be involved with the progress to AD in MCI subjects, these variants if further validated
may enable the identiﬁcation of a more homogeneous population of subjects at an earlier stage of disease for testing novel
hypotheses and/or therapies in the clinical setting.
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Introduction
Alzheimer’s disease (AD) is a complex neurodegenerative
disease with a strong genetic component. Mutations in the
amyloid precursor protein, presenlin 1 and 2 genes, have
been associated with the early-onset familial form of AD.
However,greaterthan95%ofADpatientsarediagnosedafter
the age of 65 (late-onset AD) and estimates of the heritability
for late-onset AD range from 60 to 80%.
1 The e4 allele of the
APOE gene was identiﬁed as a primary genetic risk factor for
late-onset AD.
2 Genome-wide association studies (GWAS)
have focused on disease susceptibility analysis
3–15 by
comparing allele frequencies in subjects with disease vs
non-disease controls and have identiﬁed robust genetic loci
close to genes CLU, PICALM, CR1, BIN1, EPHA1, MS4A6A,
MS4A4E and CD2AP at the genome-wide signiﬁcance
level
7,8,12,14,15 and conﬁrmed the previously reported putative
locus at CD33.
3,12
Comparing with successes in studies of disease suscept-
ibility, we have limited knowledge for the genetic loci that
are associated with disease progression beyond the
APOE e4 locus.
16 Candidate gene studies have suggested
that a variant in the TOMM40 loci may predict AD age-
of-onset in APOE e3 carriers
17 and variants in PPP3R1
18
associated with cerebrospinal ﬂuid (CSF) tau phosphorylated
at threonine 181 levels may also predict disease progression.
To date, studies using age of onset for AD diagnosis
9 or
hippocampal atrophy measured on magnetic resonance
imaging
10 as end points for GWAS analysis failed to identify
any genetic markers other than APOE or the close-by
TOMM40 loci that reached genome-wide signiﬁcance likely
due to limitations in statistical power.
9 Recently, a GWAS
study using samples from the Alzheimer’s Disease Neuroima-
ging Initiative (ADNI) consortium identiﬁed a novel variant
close to the EPC2 loci that was associated with increased
CSF total-tau levels. The analysis used a combined set of 374
subjects with AD, normal cognition or MCI, and it is unknown
whether this novel variant is predictive of the conversion of
MCI to AD.
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www.nature.com/tpBefore the current clinical diagnosis, AD subjects usually
experience a transitional period of mild cognitive impairment.
Amnestic MCI by the Petersen’s criteria deﬁnes subjects with
a primary memory component who have an elevated risk of
developing dementia of the AD type.
20 The annual rate of
diagnosis of AD in amnestic MCI subjects is approximately
10–15%, which is substantially higher when compared with
the rate of AD’s diagnosis that is observed in healthy elderly
individuals (1–2%). The recently proposed new diagnostic
guidelinesinADformalizesthediagnosisofMCIandestablish
a framework to potentially incorporate additional biomarker
data to the diagnosis of MCI due to AD.
21 Besides the APOE
e4 allele,
22 there are no genetic factors that have been
identiﬁed to be robustly associated with cognitive decline and
progression to AD in MCI subjects. Recent studies have
demonstrated that changes in the Clinical Dementia Rating-
sum of boxes (CDR-SB) can, with reasonable accuracy,
discriminate between patients with dementia of AD and those
with MCI.
23 To identify genetic markers that may be
associated with progression to AD in MCI subjects, we
conducted a GWAS using decline in clinical status as
measured in the CDR-SB as a quantitative trait in a cohort
of822amnesticMCIsubjectsforwhichwehaddatameasure-
ments up to a 48-month period.
Materials and methods
Subjects. In all, 535 MCI subjects from the Vitamin E trial
conducted by the Alzheimer’s Disease Cooperative Study
24
were genotyped in the study. All study protocols were
approved by institutional review board and informed
consent was obtained from participating subjects before
sample collection. The ADNI study includes approximately
200 AD, 300 MCI and 200 normal controls.
10,25 Top ﬁndings
from the discovery analysis of the MCI data (rs7840202,
rs12752888 or rs11637611) were contrasted with analyses
from an independent set of AD data. The GenADA set
contains 801 AD patients and 776 controls.
9 In total, 773 AD
subjects from the GenADA collection were included in the
association test for age of onset.
Genotyping. All genomic DNA samples for the Vitamin E
trial were extracted from blood and quantiﬁed using Picogreen
(Invitrogen, Carlsbad, CA, USA) before they were genotyped
at Genizon Biosciences (Montreal, Quebec, Canada) using
the Illumina 610Quad array. The ﬁnal Vitamin E data set
includes 499,134 markers after excluding markers that failed
the initial quality control (o99% call rate for all single-
nucleotide polymorphisms (SNPs) and all samples, gender
discrepancies and Mendelian errors for additional quality
control (QC) samples). The ADNI genetic data set was
downloaded from the ADNI website.
Genotype data QC. Most QC procedures were performed
using the genetic analysis package PLINK (http://pngu.mgh.
harvard.edu/~purcell/plink/).
26 Similar criteria were applied
for all Illumina data sets: SNPs with a minor allele frequency
Z1% and SNP and sample call rate Z99% were retained;
SNPs out of Hardy–Weinberg equilibrium in the control
population ( log10(P-value)45) were excluded; duplicated
samples and samples with any possible identiﬁcation errors
were excluded; and the analysis only included Caucasian
samples identiﬁed via multi-dimensional scaling after
merging with the HapMap data. No imputation was carried
out for the GWAS analysis.
We adapted the QC procedure from the original GenADA
sample set to accommodate a different genotyping platform
(Affymetrix 550K). GenADA genotype data (after QC) were
imputed by Mach (http://www.sph.umich.edu/csg/abecasis/
mach/) using reference haplotypes from HapMap III phased
data (release 2). A two-step imputation was performed for
GenADA to investigate the top two variants for association
with age of onset. Variant rs7840202 had an imputation
quality score of 0.90 and an r
2 value of 0.84 in GenADA data
set. Variant rs11637611 had a quality score and r
2 value of 1
in GenADA data set.
Statistical analysis. CDR-SB data were available for up
to 48 months for 822 genotyped MCI Caucasian patients
from Vitamin E trial and ADNI (78% subjects have data at
24 months). The statistical model used for progression was
a repeated-measures analysis of variance with covariates
of study, baseline age, baseline Mini-Mental State Examin-
ation (MMSE), baseline CDR sum of boxes, gender and
APOE e4 carrier status (þ/ ). The response variable was
the change from baseline of CDR-SB, and the primary
factors of interest were months and genotype, with their
interaction used to assess the effect of genotype on progres-
sion. Because progression of cognitive defects may be
nonlinear, a more general approach was taken, with time
points treated as nominal to allow for nonlinear or piece-
wise linear changes in CDR-SB over time. A signiﬁcant
genotype time interaction implies that the changes in
CDR-SB over time are different depending on genotype.
This model is used frequently at Pﬁzer for assessing treat-
ment effects in clinical trials; here, ‘treatment’ is replaced with
‘genotype’. Data at a maximum of ﬁve time points (6, 12, 18,
24 and 30 months) were used.
The random subject effect was assumed to have compound
symmetric variance–covariance matrix. This is similar to the
modelusedbyCruchagaetal.,
18modiﬁedtoallowforvariations
in slope over time by treating time (months) as categorical.
The genotype time interaction was the factor of primary
interest. A signiﬁcant genotype time interaction implies a
different time course of progression depending on genotype,
in contrast to a signiﬁcant main genotype effect, which implies
a different mean change in CDR-SB over the time course
depending on genotype. The reported P-value is based on the
type III sum of squares for the interaction term, which
assesses the effect of the interaction between genotype and
time after all the main effects (including time and genotype)
have been accounted for. These P-values were adjusted for
genome-wide signiﬁcance based on the null distribution of the
interaction test statistic. To assess the null distribution of the
interaction test statistic for this data set, a series of 4300000
random univariate genotypes based on empirical genotype
distributions (that is, sampled from the observed genotype
frequencies) were applied to the subjects and over 300000
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percentile of the distribution of interaction P-values was
0.000378. Applying the Bonferroni correction for 1 million
SNPs to this percentile gives a cutoff for the interaction
P-value of 3.78 10
 10 to have a family-wise type I error rate
of no more than 1%. This is a stricter cutoff than the
usual GWAS criterion, and was necessary since the overall
progression of the cohort could inﬂate the signiﬁcance
of the interaction effect if the correct null distribution is
not applied.
To identify effects that could be clinically meaningful, a
prospective ﬁlter on the results was applied. SNPs showing
statistically signiﬁcant genotype time interactions based on
the model and criterion described above were selected for
further consideration if they passed all three rules for the ﬁlter.
SNPs were ﬁltered using the following rules: (1) a single
genotype must have the maximum (minimum) progression
(numerical change from baseline) at each of the time points of
12, 18, 24 and 30 months. The time point of 6 months was
considered too early to require a consistent signal that soon.
(2) The change from baseline at 24 months for that genotype
must be statistically different from at least one of the other two
genotypesat a level of 0.05. (3) The difference in least-square
means between the two genotypes must be at least 1 point on
the CDR-SB scale, to assure clinical relevance.
Those top SNPs that passed genome-wide signiﬁcance
level and also passed the ﬁlters were further assessed for
consistency of results by employing another cognitive
measure ADAS-13 (AD Assessment Scale 13 item) as the
end point (the model is similar to the one described as above,
except replacing CDR-SB with ADAS-13). We also analyzed
the time to conversion from MCI to AD, based on diagnostic
changes as recorded by the investigators in each study. The
ﬁrst date when the diagnosis changed from MCI to probable
AD was noted. Subjects without conversion were considered
to be censored at their last recorded visit date that still had a
diagnosis available. The Cox proportional hazards model was
used. For the age-of-onset analysis in the GenADA set, which
does not contain longitudinal cognition data, we conducted
analysis of covariance analysis including APOE e4 status
(þ/ ) and gender. The models compared cases homozy-
gousforthe minoralleletothe othertwo genotypesforeachof
the three variants.
CSF biomarkers werelog10 transformedand assessed in a
recessive analysis of covariance model that adjusted for age,
sex and baseline clinical diagnosis (AD, MCI, control).
We combined rs7840202, rs12752888 and rs11637611 to
deﬁne a FastP (fast progression) status. Patients with any of
the minor homozygous genotypes from the top three markers
were deﬁned as FastP group and the other patients without
any of the minor homozygous genotypes were non-FastP
group. Disease progression and conversion analysis were
described as above.
Results
Sample/data set characteristics. We conducted a GWAS
study in 489 MCI Caucasian cases collected through the
Vitamin E MCI trial (Vitamin E MCI)
18 combined with 333
Caucasian MCI patients from the ADNI data set (ADNI
MCI)
10,25 for which longitudinal cognitive measures were
available for up to 48 months (Table 1). Both studies included
amnestic MCI subjects according to the Peterson’s criteria
27
without any other neurological diseases or any psychiatric
disorder as described in DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition). Characteristics of
these two sample sets were similar for baseline scores (MMSE,
CDR-SB) as well as age distribution (Table 1). A majority of
subjects in the combined data set had longitudinal CDR-SB
scores evaluated up to 24 (78.3%) and 36 months (52.7%). The
ADNI MCI cohort included more male subjects (64.3 vs 54.0%)
and slightly fewer subjects with the APOE e4 (54.5 vs 58.5%)
allele when compared with subjects from the Vitamin E trial.
All genotyping data obtained from the Illumina 610 platform
for the combined data sets were processed through a strict
quality control process (see Materials and methods for
details). A linear repeated measures model was used to
examine the contributions of genetic variants on disease
progression adjusted for study (Vitamin E or ADNI), baseline
age,gender,baselineMMSE,baselineCDR-SBandAPOEe4
status. A similar model has been previously used to model
disease progression.
18 Our model treats time (months) as
categorical rather than continuous, to allow for the possibility
that the progression rate was not constant over time.
We observed that study (Po0.01), baseline MMSE
scores (Po10
 9), baseline age (Po0.001) and APOE e4
status (Po10
 4) signiﬁcantly contributed to the progression
rate as measured by the change in clinical status (CDR-SB).
These observations were consistent for all of the variants
tested in our analysis.
Table 1 Summary of baseline sample characteristics
a
Sample set (N) Age
(mean±s.d.)
Baseline CDR-SB
(mean±s.d.
a)
Baseline MMSE
(mean±s.d.
a)
Gender
(% male)
APOE status
(% e4 carriers)
b
ADNI (333 MCI) 75.0±7.14 1.6±0.88 27.1±1.75 64.3 54.5
Vitamin E Trial (489 MCI) 73.0±7.11 1.8±0.78 27.4±1.75 54.0 58.5
Combined (822 MCI) 73.9±7.18 1.7±0.82 27.3±1.76 58.2 57.3
GenADA (783 AD) 72.2±8.49 NA NA 42.5 62.8
Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; CDR-SB, Clinical Dementia Rating-sum of boxes; MCI, mild cognitive
impairment; MMSE, Mini-Mental State Examination; NA, not applicable; s.d., standard deviation.
aOnly Caucasian subjects are included in the analysis and reported here.
bAPOE e4 carriers include subjects with one or two copies of e4 allele at the APOE locus.
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susceptibility are not strongly associated with disease
progression in subjects with amnestic MCI. We ﬁrst
tested the association of cognitive decline with the pre-
speciﬁed candidate variants in CLU (rs11136000), PICALM
(rs3851179), CR1 (rs3818361) and BIN1 (rs744373) that had
been identiﬁed in previous disease susceptibility studies.
7,8,12
None of these candidate variants were signiﬁcantly asso-
ciated with the rate of disease progression after multiple
testing corrections in our data set (Table 2). The PICALM
variant (rs3851179) showed a nominal association
(P¼0.027, corrected P¼0.108) with the AA carriers having
a slower rate of decline when compared to the AG/GG
carriers. This result is consistent with the previously reported
protective effect of the A allele for AD susceptibility.
7
We also conducted a post-hoc analysis of the recently
identiﬁed variants in EPHA1, MS4A6A, MS4A4E and CD33
(Table 2). Genotype data for the top variant in CD2AP
(rs9349407) were not available in our data set. The EPHA1
variant (rs11767557) showed a nominal association
(P¼0.013, corrected P¼0.065) with the rate of decline. This
association is primarily driven by the CC carriers having a
slower progression toward the end of the study period, but is
not consistent over the full course of observation. None of the
other previously identiﬁed variants contribute to disease
progression in our sample set (Table 2).
GWAS analysis identiﬁed multiple novel loci associated
with the rate of progression in subjects of MCI. We next
conducted an unbiased GWAS analysis in the sample set.
SNPs with rare genotype counts (o5% for any individual
genotype group) were removed to avoid technical artifacts
(233603 SNPs were included in the ﬁnal analysis). Our
GWAS analysis (QQ plot was presented in Supplementary
Figure S2) identiﬁed 23 variants that reached genome-wide
signiﬁcance level at the false-positive rate of 0.01 (Bonferroni
correction for 1 million SNPs based on simulated P-value null
distribution, P-value o3.78 10
 10). In total, 11 variants
were selected, which demonstrated a consistent genotype
effect on disease progression at each of the time points
examined, with the possible exception of the 6-month time
point that produced an inconsistent signal owing to the
variability at this early time point (Supplementary
Table S1). These variants were also selected based on
potential clinical utility, deﬁned as at least 1 point difference
in estimated CDR-SB scores between the fastest and
slowest progressing genotype groups at 24 months. None
of the SNPs deviated from Hardy–Weinberg equilibrium
(Supplementary Table S1). The most signiﬁcant SNPs that
reached genome-wide signiﬁcance level included: rs7840202
on chr8, rs12752888 on chr1 and nine SNPs on chr15.
The SNPs on chr15 appeared to have very similar allele
frequencies and are in high linkage disequilibrium (pair-wise
correlation coefﬁcient r
2X0.64; Supplementary Figure S1).
We selected rs11637611 (with the smallest P-value) to
represent the chr15 region.
All the top variants were found to have consistent effects in
eachoftheindependentsamplesetsthatweprobed(Table3).
Two SNPs reached genome-wide signiﬁcance in the Vitamin
E MCI trial alone (P-values for rs1275288 and rs11637611
passed a false-positive rate of 0.05 after adjusting for 1 million
SNPs; Po8.31 10
 9). The other SNP (rs7840202,
P¼5.71 10
 7) did not reach genome-wide signiﬁcance
levelintheVitaminE MCItrialalone, butwashighlysigniﬁcant
whencombined withtheADNIsample set(Table 3).For these
variants, the minor homozygous genotype group had
greater disease progression over the study period (Figure 1).
Importantly, the effect of the risk genotypes is independent of
and additive to other factors such as baseline age, gender
and APOE e4 status (þ/ ) that are known to inﬂuence
progression.
rs7840202, rs12752888 or rs11637611 are also
associated with the rate of decline in cognition and
conversion of amnestic MCI to a diagnosis of AD. We
further tested the association of the variants that were
identiﬁed with a faster rate of increase in disease severity
with related, but different cognitive endpoints to conﬁrm our
Table 2 Candidate variants identiﬁed from recent GWAS scans for AD susceptibility
a
SNP Gene Chr. Position
(b.p.)
Minor allele
frequency
Genotype time interaction
nominal P-value
Bonferroni
corrected P-value
b
Pre-speciﬁed
rs3818361 CLU 8 27520436 0.38 0.948 1
rs3851179 PICALM 11 85546288 0.34 0.027 0.108
rs3818361 CR1 1 205851591 0.22 0.933 1
rs744373 BIN1 2 127611085 0.3 0.566 1
Post hoc
rs11767557 EPHA1 7 142819261 0.19 0.013 0.065
rs3865444 CD33 19 56419774 0.29 0.439 1
rs3764650 ABCA7 19 997520 0.10 0.804 1
rs610932 MS4A6A 11 59695883 0.44 0.840 1
rs670139 MS4A6A/MS4A4E 11 59728371 0.41 0.592 1
rs9349407 CD2AP 6 47561337 NA NA NA
Abbreviations:AD,Alzheimer’sdisease;CDR-SB,ClinicalDementiaRating-sumofboxes;MMSE,Mini-MentalStateExamination;GWAS,genome-wideassociation
studies; NA, not applicable; SNP, single-nucleotide polymorphism.
aThe analysis was performed with experimentally obtained genotype data using change of CDR-SB as end point and a repeated mixed model to adjust for study,
baseline age, gender, baseline MMSE, baseline CDR-SB and APOE e4 status (+/ ).
bVariants in CLU, PICALM, CR1 and BIN1 were pre-speciﬁed, whereas the other recently reported variants were investigated after the primary analysis.
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rate of disease progression as measured by a signiﬁcant
increase in the CDR-SB demonstrated signiﬁcant
associations with changes in the ADAS-13 from baseline
after adjusting for baseline age, gender, APOE, baseline
MMSE and baseline ADAS-13 scores (genotype months
interaction P-value—rs7840202: 2.09 10
 13; rs11637611:
1.5 10
 3; rs12752888: 7.8 10
 3). Furthermore, the effect
sizes from the genotype groups are consistent for the two
measures (Table S2).
Next, we examined whether or not the top three variants
(rs11637611, rs7840202 and rs12752888) that we had
identiﬁed to be associated with disease progression were
associated with the time to develop possible or probably AD
according to the criteria deﬁned by NINCDS-ADRDA
(National Institute of Neurological and Communicative Dis-
eases and Stroke and the Alzheimer’s Disease and Related
DisorderAssociation).TheconversionofsubjectsfromMCIto
AD was based on diagnostic changes as recorded by the
investigators in each study (Figure 2). For all of the variants
that we identiﬁed, the minor homozygous genotype groups
had an increased probability of converting to AD (rs7840202,
hazard ratio¼2.26, 95% conﬁdence interval [1.56, 3.26];
rs12752888, hazard ratio¼1.78, 95% conﬁdence interval
[1.21, 2.64]; rs11637611, hazard ratio¼2.15, 95% conﬁ-
dence interval [1.40, 3.31]) when compared with the other
genotype groups. The increased probability of converting to
AD for all of the minor allele variants that we discovered were
of a similar magnitude as that which has been previously
reported for MCI subjects who are APOE e4 carriers (hazard
ratio¼2.25, 95% conﬁdence interval [1.73, 2.9]). Further-
more, a stratiﬁed analysis according to APOE e4 status
indicated that the effect of rs7840202, rs11637611 or
rs1275288 for conversion to AD is observed in both APOE
e4 carriers and non-carriers (Figure 2).
rs7840202 and rs11637611 are associated with an earlier
age-of-onset in an independent AD set. MCI subjects with
a faster rate of disease progression may, in theory, have an
earlier age of AD onset. We therefore investigated whether
the novel loci that we had identiﬁed to be associated with a
more rapid rate of disease progression (rs11637611 and
rs7840202) were associated with an earlier age of disease
onset in an independent data set. This analysis comprised
772 AD subjects from the GenADA sample set who met the
ADRDA/NINCDS criteria for diagnosis of probable AD and
whose age-of-onset information had been collected.
9
Genotype data from the rs12752888 SNP were not
available in this data set. Both the rs7840202 and
rs11637611 SNPs were modestly associated with an earlier
age of disease onset in AD subjects that was independent of
APOE e4 carrier status and gender (rs7840202: P¼0.04;
rs11637611: P¼0.05). On average, carriers for the CC
genotype were diagnosed with AD at a younger age
(rs7840202: age difference estimate¼ 1.93 years;
rs11637611: age difference estimate¼ 2.5) when
compared with the age of disease diagnosis in individuals
representing the other genotypes. This earlier age of disease
onset (approximately 2 years) in AD subjects whose
genotype is the minor homozygous allele groups in
rs7840202 and rs11637611, represents a larger effect
when compared with the effect by APOE e4 carrier status,
which is approximately  1.04 years in the same data set.
Note that longitudinal clinical decline is a more accurate
assessment compared with age of onset, which may not be
consistently measured in different sample sets and may
show varying results even for the effect of the APOE e4
variant. Nevertheless, the results support the hypothesis that
these variants potentially deﬁne a group of MCI subjects with
a faster cognitive decline that might also be associated with
an earlier age of AD onset.
Combining rs7840202, rs12752888 or rs11637611
information (FastP) deﬁnes a larger population of
FastP that may be additive to CSF–biomarkers for
patient selection. Although each of the top variants is
strongly associated with disease progression in MCI subjects
alone, each variant only deﬁnes a relatively small group
Table 3 Top markers associated with the rate of progression from the GWAS analysis in MCI subjects
a
SNP UCSD ADNI Combined
Geno Least-square
mean estimate
(24 months)
Genotype time
interaction
P-value
b
Geno Least-square
mean estimate
(24 months)
Genotype time
interaction
P-value
b
Geno Least-square
mean estimate
(24 months)
Genotype time
interaction
P-value
b
rs7840202 CC 2.59 5.71E-07 CC 2.82 2.48E-05 CC 2.692 4.27E-14
CA 0.94 CA 1.55 CA 1.192
AA 0.66 AA 1.25 AA 0.899
rs11637611
c CC 2.92 9.38E-10 CC 2.7 4.80E-06 CC 2.826 1.07E-15
CT 0.78 CT 1.19 CT 0.947
TT 0.79 TT 1.64 TT 1.138
rs12752888 CC 2.18 2.48E-10 CC 1.97 3.30E-01 CC 2.076 3.08E-11
CT 0.92 CT 1.64 CT 1.221
TT 0.69 TT 1.39 TT 0.992
Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging Initiative; CDR-SB, Clinical Dementia Rating-sum of boxes; Geno, genotype; GWAS, genome-wide
association studies; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; SNP, single-nucleotide polymorphism.
aGWAS analysis was performed with experimentally obtained genotype data using change of CDR-SB as end point and a repeated mixed model to adjust for study,
baseline age, gender, baseline MMSE, baseline CDR-SB and APOE e4 status (+/ ).
bNominal Po3.78 10
 10 reﬂects genome-wide correction (1 million SNPs) for family-wide error rate of no 40.01 based on 300000 simulations from the null
distribution.
cOther SNPs in the region (listed in Supplementary Table S1) are also strongly associated with disease progression.
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individually. However, there is minimal correlation among the
genetic variants and it is possible to combine them to deﬁne a
larger MCI population (approximately 16.6%). MCI subjects
can be deﬁned by a FastP status by the presence of the
minor homozygous genotype for at least one of the three
variants that we identiﬁed (FastP group). When compared
with MCI subjects where the minor homozygous genotype is
completely absent (non-FastP group), there is a signiﬁcant
difference in the disease progression proﬁle (genotype time
interaction: P¼1.66 10
 31; Figure 3). The CDR-SB change
from baseline least-square mean estimate at 24 months is
2.33 for FastP group and only 0.92 for non-FastP group. The
effect of FastP status on disease progression was similar for
each study cohort (2.44 for FastP group and 1.32 for non-
FastP group in the ADNI MCI subjects; 2.25 for FastP group
and 0.65 for non-FastP group in the Vitamin E MCI cohort).
Next, we probed whether or not FastP status would inﬂuence
the conversion to AD dementia in MCI subjects. Although a
higher percentage of MCI subjects are projected to convert to
AD in the Vitamin MCI trial vs ADNI MCI, FastP group
consistently had a signiﬁcant increased rate of conversion to
AD independent of APOE e4 carrier status when compared
with non-FastP group in each of the two independent sample
sets that we analyzed (Figure 4).
Biomarker data such as baseline CSF Ab and tau levels
have been previously shown to be associated with the
diagnosis of AD in MCI subjects.
28 We also investigated
whether the FastP signature can be additive to the other CSF
biomarkers. The analysis was limited to the subjects in the
ADNI cohort with both CSF and genotype data (n¼173) as
CSF biomarker data were not collected for the Vitamin E MCI
subjects. Subjects with CSF amyloid-b 1–42 peptide (Ab1 42)
levels p192pgml
 1 in the ADNI set had been shown to
decline more rapidly than subjects above the cutoff.
29 In that
subset of subjects (n¼133), the FastP group had a
Figure 1 rs11637611, rs7840202 and rs12752888 deﬁne sub-populations with
different progression rates in 822 subjects of mild cognitive impairment (MCI).
Least-square means were estimated for Clinical Dementia Rating (CDR)-sum of
boxes scores over time by genotype groups. Ninety-ﬁve percent conﬁdence
intervals were shown for each time point. At least 78% of patients contributed data
to 6, 12, 18 and 24 months. Close to half of the patients contributed data at 30
months.
Figure 2 Kaplan–Meier estimates of the rate of conversion from mild cognitive
impairment (MCI) to Alzheimer’s disease (AD) for rs7840202, rs11637611 or
rs12752888. Panels showed the effect of genotypes (CC is the minor homozygous
genotype group vs non-CC groups) on the rate of conversion from MCI to AD
diagnosis in APOE e4 carriers (þ) and non-carriers ( ). The Cox proportional
hazards model was used.
Alzheimer’s disease progression in subjects with mild cognitive impairment
XH uet al
6
Translational Psychiatrysigniﬁcantly faster rate of decline when compared with the
non-FastP group (change in CDR-SB, P¼0.028), with an
increasing effect at the 24-month time point.
Discussion
To date, the majority of GWAS studies have focused on
genes associated with AD disease status. In this study, we
undertook a GWAS that utilized disease progression as
deﬁned by a change in the CDR-SB score over time as a
quantitative trait in Caucasiansubjects with MCI. Byusingthis
approach, we identiﬁed several novel variants that appear
to be associated with disease progression in MCI subjects
and that are independent of other genetic loci that affect
disease susceptibility.
7,8,12 None of the candidate variants
identiﬁed from the recent GWAS susceptibility study seem to
have large effect in disease progression in our sample set.
We identiﬁed several novel variants in which the minor
homozygous genotype groups are associated with a signi-
ﬁcantly faster rate of disease progression as measured by
increase in the CDR-SB and ADAS-13. In addition, inheri-
tance of the minor homozygous genotype for each of these
novel variants (rs7840202, rs12752888 or rs11637611) was
also associated with a signiﬁcantly increased likelihood of
conversion from MCI status to AD. We validated our ﬁnd-
ings of an association for the minor homozygous genotype
carriers for rs7840202 and rs11637611 with an earlier age
of disease onset in an independent cross-sectional set of
AD subjects, consistent with the expectation that the minor
homozygous genotype group is associated with a faster
rate of disease progression. Note that changes in cognitive
decline is a more sensitive measure compared with age
of onset, which may not be accurately assessed and
could potentially introduce inconsistencies across data sets.
To our knowledge, these novel variants are the ﬁrst loci
that are robustly associated with the progression of
disease that reached genome-wide signiﬁcance level in the
combined set.
Figure 3 Fast progression (FastP) group with any of the risk genotypes in
rs7840202, rs11637611 or rs12752888 deﬁne different rate of progression
compared with non-FastP group without any of the risk genotypes. Panels a–c
showedtheleast-squaremeanestimatesforClinicalDementiaRating-sumofboxes
(CDR-SB):(a)forAlzheimer’sDiseaseNeuroimagingInitiative(ADNI)mildcognitive
impairment (MCI)subjects; (b)for VitaminE MCIsubjects; and(c) for the combined
sample set.
Figure 4 Kaplan–Meier estimates of the rate of conversion from mild cognitive
impairment (MCI) to Alzheimer’s disease (AD) dementia for the fast progression
(FastP) group and non-FastP group. Panels a–d showed the Kaplan–Meier
estimates for the conversion of MCI to AD. Panels showed results (a) for
Alzheimer’s Disease Neuroimaging Initiative (ADNI) MCI subjects; (b) for Vitamin
early MCI (E MCI) subjects;(c) and (d) for thestratiﬁed analysisaccordingto APOE
e4 status (þ/ ) in the combined MCI sample set.
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relatively small fraction of the MCI population that has a faster
rate of disease progression, in aggregate they deﬁne
approximately 16.6% of the MCI population (FastP group).
Moreover, the estimated difference in the changes in the
CDR-SB at 24 months between the FastP group and non-
FastP group is 1.40 and highly signiﬁcant (P¼1.87 10
 21).
This large effect is independent of APOE e4 carrier status and
can therefore be potentially utilized to model disease
progression in clinical trials. We observed a signiﬁcant study
effect for the variants, but the estimates for mean change of
CDR-SB at 24 months are similar for these variants and
consistent for the two independent studies (Table 3).
CSF biomarker data were available for only a small subset
of the ADNI set (n¼174 with baseline data). Combined with
the low frequency of the genotypes for each variant (5–7%),
this limits the statistical power to detect association of the
variants with either CSF Ab1 42 or total-tau levels. We
observed a borderline association with phosphorylated-tau
(tau phosphorylated at threonine181 (p-tau181p)) for
rs7840202 (Supplementary Table S3). Subjects with CSF
Ab1 42 levels p192pgml
 1 in the ADNI set declined more
rapidly than subjects above the cutoff.
29 After combining
subjects with any of the fast progress genotypes to a FastP
status, we observed a moderately signiﬁcant contribution of
the FastP signature in a subset of MCI patients with lower
baseline CSF-Ab1 42 levels (o192ngml
 1), suggesting that
the signature may be additive to the known CSF biomarkers
such as CSF Ab1 42.
Inadditiontothe potentialofutilizing FastP groupfortesting
clinical candidates, the novel variants that we have identiﬁed
that are associated with a more rapid rate of disease
progression over time may provide insights into the mechan-
istic basis for disease progression. We deﬁned a linkage
disequilibrium region for each locus by identifying all variants
with pair-wise r
2X0.5 in the HapMap Caucasian subjects and
extended the furthest SNPs into the haplotype block
boundaries (see Supplementary Table S4 for all region
boundaries). The region for rs1275288 contains a single
gene:ACOT11(amemberoftheacyl-CoAthioesterasefamily
that catalyzes the conversion of activated fatty acids); the
region for rs7840202 includes two genes: UBR5 (ubiquitin
protein ligase E3 component n-recognin 5) and RRM2B
(ribonucleotide reductase M2 B); and the variants on
chr15q23 (top variant rs11637611) deﬁne a large genomic
region containing multiple genes (MYO9A, SENP8,
GRAMD2, PKM2, CELF6, PARP6, HEXA and ARIH1),
including the HEXA gene, which had been identiﬁed in a
lysosomal storage disease, Tay–Sachs disease. We em-
ployed various in silico techniques to prioritize the gene
candidates based on the potential regulatory effect of the
variants on gene expression (eQTL) and also non-random
connections among these gene candidates through
word-usage in PubMed abstracts (GRAIL) (Supplementary
Figure S3). The eQTL browser (http://www.eqtl.uchicago.
edu/cgi-bin/gbrowse/eqtl/) did not reveal any strong
cis-effects for the variants, but this may be largely limited by
the availability of the variants/transcripts on the tested
platforms and we cannot also exclude the possibility that
these variants may be speciﬁc to any activity-induced
expression patterns. We expanded the GRAIL analysis to
include additional loci associated with rate of decline below
genome-wide signiﬁcance level in the GWAS analysis
(rs1412451, rs582420, rs7678888 and rs1958399), which
did not pass our selection ﬁlter owing to lower potential for
clinical utility (the estimated differences between the fastest
and slowest genotype groups for CDR-SB scores were
less than 1 point at 24 months) (Supplementary Table S4).
The GRAIL analysis (Supplementary Figure S3) suggested
connections between PTPRM (rs582420) and EPHA5
(rs7678888), which are associated with tyrosine phosphoryla-
tion and axon guidance. The EPHA5 variant associated with
disease progression is independent of the EPHA1 variant for
the disease susceptibility (correlation coefﬁcient: r
2¼0.017)
and together support the roles of ephrin receptors for AD
etiology.
30 It also highlighted connections among UBR5,
ARIH1 and SENP8 (Supplementary Figure S3), which are
associated with the ubiquitination process. Ubiquitination was
reported to play a role in synaptic plasticity as well as other
neurological diseases such as UBE3A in Angelman’s syn-
drome
31 and PARK2 gene (parkin) in familial Parkinson’s
disease.
31 A previous report
32 indicated that UBR5 expres-
sion is elevated in pyramidal cells from multiple regions of
post-mortem AD brain including hippocampus as compared
with the same regions from aged normal brain tissue. We also
observed a similar increase in UBR5 mRNA levels in samples
analyzed from AD vs control (Supplementary Figure S3),
supporting the need for further elucidation of the role of UBR5
and ubiquitin ligases in AD biology.
Further investigation and replication studies will be required
to fully validate and elucidate the roles the novel variants that
we have identiﬁed here. However, our results demonstrate
thatit is possible toidentify genetic factors associated with the
rate of decline in a cohort of MCI subjects where sufﬁcient
longitudinal data exists. Elucidation of the biological pathways
thatare involved withdiseaseprogressioninvarious stagesof
the disease may reveal novel targets that are amenable to
drugdiscoveryeffortsandintheshorttermmayprovideuseful
tools to identify an enriched population of fast progressors.
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